Bryce Point Capital LLC Buys New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bryce Point Capital LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,953 shares of the medical research company’s stock, valued at approximately $1,536,000.

A number of other institutional investors have also made changes to their positions in TMO. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $26,000. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. Pillar Financial Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Missouri Trust & Investment Co acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock valued at $13,106,062 over the last ninety days. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 3.0 %

Shares of NYSE TMO opened at $482.51 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $481.21 and a 52 week high of $627.88. The stock’s fifty day moving average is $538.56 and its 200 day moving average is $550.11. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $182.03 billion, a P/E ratio of 29.19, a PEG ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.36%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is 10.41%.

Analyst Ratings Changes

Several analysts have issued reports on TMO shares. Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Scotiabank raised their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Bank of America lowered their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Finally, Citigroup dropped their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.